lopinavir + ritonavir + hydroxychloroquine + azithromycin + tocilizumab + methylprednisolone + anakinra + enoxaparin

This drug entry refers to a specific multi-drug standard medical treatment protocol utilized by the **Fundacion Clinic per a la Recerca Biomédica** in clinical trials for COVID-19, particularly for critically ill patients requiring invasive mechanical ventilation. The regimen is a complex combination therapy designed to address multiple facets of the disease pathology. It includes the antiviral combination **lopinavir/ritonavir** (Kaletra) to inhibit viral replication; **hydroxychloroquine** and **azithromycin** for their potential antiviral and immunomodulatory effects; the interleukin-6 (IL-6) receptor antagonist **tocilizumab** and the interleukin-1 (IL-1) receptor antagonist **anakinra** to mitigate the inflammatory cytokine storm; the corticosteroid **methylprednisolone** for systemic anti-inflammatory action; and the low molecular weight heparin **enoxaparin** (Clexane) to prevent COVID-19-associated coagulopathy and thrombotic events.

Other names

standar medical treatmen-Fundacion Clinic per a la Recerca Biomédica-COVID-19Standard medical treatment (Fundacion Clinic COVID-19 Protocol)Standard medical treatment for COVID-19